CEPI/BC 2020年3月12-13日会议共识摘要:COVID-19疫苗疾病增强风险评估
2020年3月12-13日,流行病防范创新联盟(CEPI)与布莱顿协作(BC)疫苗安全平台(SPEAC)召集疫苗免疫学与冠状病毒领域专家召开科学工作会议。会议鉴于部分MERS和SARS-CoV-1疫苗在动物模型中显示疾病增强证据,而SARS-CoV-2疫苗存在类似担忧,讨论了可降低安全顾虑的疫苗设计,以及动物模型和早期临床试验免疫学评估如何帮助评估风险。本报告总结所呈现证据,并为加速疫苗研发中的COVID-19候选疫苗安全性评估提供考量。
要点
- 部分MERS和SARS-CoV-1疫苗在动物模型中显示疾病增强证据,这是SARS-CoV-2疫苗的特别关切。
- 过去少数病毒疫苗报告过疾病增强综合征,免疫者后续接触病毒时出现严重程度增加或死亡,或感染频率增加。
- 动物模型曾帮助确定RSV疫苗疾病增强的机制,并用于设计和筛选新的RSV候选疫苗。
- 快速研发的主要挑战是通过周密的疫苗设计和及时全面评估来避免安全性问题。
- 会议讨论了何种疫苗设计可降低安全顾虑,以及动物模型和早期临床试验免疫学评估如何帮助评估风险。
研究设计与关键结果
- CEPI与BC SPEAC于2020年3月12日和13日召集疫苗免疫学与冠状病毒领域专家举行科学工作会议。
- 会议目的是考虑何种疫苗设计可降低安全顾虑,以及动物模型和早期临床试验免疫学评估如何帮助评估风险。
- 报告总结所呈现证据,并为加速疫苗研发中的COVID-19候选疫苗安全性评估提供考量。
证据类型、等级与局限
- 证据类型:专家工作会议共识摘要报告。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,COVID-19疫苗快速开发中需通过周密的疫苗设计和及时全面评估来避免安全性问题。
- 作者认为,鉴于部分MERS和SARS-CoV-1疫苗在动物模型中显示疾病增强证据,SARS-CoV-2疫苗的疾病增强风险需特别关注。
指南或共识出处
- CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.
参考来源
- Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020. PMID: 32507409. doi:10.1016/j.vaccine.2020.05.064
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。